{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065672","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.416823+00:00","generated_at":"2026-05-22T06:51:07.576464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025","bullets":["Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)","Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M","DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served","COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026","2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065672","json":"https://secwatch.observer/filing/0000950170-25-065672.json","markdown":"https://secwatch.observer/filing/0000950170-25-065672.md","text":"https://secwatch.observer/filing/0000950170-25-065672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/0000950170-25-065672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:51:07.576464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}